TITLE

MOMETASONE-BASED TRIPLE COMBINATION THERAPY IN MELASMA: IS IT REALLY SAFE?

AUTHOR(S)
Imran Majid
PUB. DATE
October 2010
SOURCE
Indian Journal of Dermatology;Oct-Dec2010, Vol. 55 Issue 4, p359
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Kligman's triple combination formula has been one of the most popular treatment options in melasma over the last three decades. The original Kligman's formula has been modified in many ways over the years and the most recent modification that has been introduced is a triple combination of 2% hydroquinone, 0.025% tretinoin, and 1% mometasone. The use of this triple combination in patients with melasma has seen a sharp rise over the last few years and with this rampant use the side-effect profile of this triple combination has also come to the fore. Aim: The aim of the present study was to assess the overall safety of the mometasone-based triple combination treatment in the management of melasma. Materials and Methods: This retrospective study was performed on 60 patients of melasma who had used a mometasone-based triple combination treatment for at least 3 weeks anytime in the previous 1 year. The patients were given a preformed questionnaire wherein they assessed the overall effect of the triple combination treatment on their melasma during its use as well as after its withdrawal. The patients were specifically asked about the status of their disease as well as the sun sensitivity of their skin before and after the use of triple combination treatment. In addition, the patients were assessed by a single trained dermatologist for the presence of any adverse effects arising out of the triple combination treatment in the form of telangiectasia, hypertrichosis, acne, skin atrophy, etc. Results: Majority of patients (51.7%) had used the combination treatment well beyond the recommended duration. About one-third (36.7%) of the patients rated their melasma as worse at the time of filling the questionnaire as compared with their disease before the use of triple combination treatment. On clinical examination, the evidence of steroid side effects was seen in 26 patients (43.3%). Steroid-induced telangiectasia was the commonest finding, seen in all of these 26 patients. Steroid-induced skin atrophy, hypertrichosis, and acneiform eruption were seen in 19, 17, and 11 patients, respectively. Conclusions: The propensity of a mometasone-based triple combination treatment to cause steroid adverse effects on the facial skin should always be borne in mind when the same is prescribed as a treatment option in melasma.
ACCESSION #
57270729

 

Related Articles

  • Triple-combo cream treats chronic, recurrent melasma. Guttman, Cheryl // Dermatology Times;Sep2004, Vol. 25 Issue 9, p82 

    Reports on the study which found the efficacy and safety of the fixed triple-combination cream as a modality for the long-term management of melasma, a dermatological condition. Advice for patients on sun avoidance; Design of the extension study to establish long-term safety; Improvement of...

  • CE Questions.  // Drug Formulary Review;May2008 Supplement, Vol. 24, Special section p4 

    A quiz concerning on the clinical efficacy, safety, and effectiveness of the therapeutic agent Rivastigmine is presented.

  • Management of Seborrheic Dermatitis and Pityriasis Versicolor. Faergemann, J. // American Journal of Clinical Dermatology;Mar/Apr2000, Vol. 1 Issue 2, p75 

    Pityriasis (tinea) versicolor and seborrheic dermatitis are two very common skin diseases. Pityriasis versicolor is a chronic superficial fungal disease usually located on the upper trunk, neck, or upper arms. In pityriasis versicolor, the lipophilic yeast Malassezia (also know as Pityrosporum...

  • Immunosuppressive agents beneficial for some diseases. Kuznar, Wayne // Dermatology Times;Jul95, Vol. 16 Issue 7, p47 

    Reports on immunosuppressive agents with beneficial effects on patients with dermatologic diseases, according to Jeffrey Callen. Methotrexate; Azathioprine; Cyclosporine; Interferon alpha-2a; Intravenous immune globulin; Other therapies found to be effective in treating dermatologic diseases.

  • News Briefs.  // Dermatology Times;Dec2001, Vol. 22 Issue 12, p3 

    Reports developments on the treatment of skin diseases in the United States as of December 2001. Assessment on the efficacy of the drug in patients with psoriatic arthritis; Approval of corticosteroids for children with atopic dermatitis; Association between nevirapine use and increase risk of...

  • Moxifloxacin: A Viewpoint by N.S. Sadick. Sadick, N.S. // Drugs;2002, Vol. 62 Issue 6, p974 

    Comments on the development of antibacterial agent, moxifloxacin for the treatment of skin and soft-tissue bacterial infections. Advantage in terms of patient compliance; Efficacy in the treatment of uncomplicated skin structure infections; Precautions for patients in taking moxifloxacin.

  • Moxifloxacin: In Uncomplicated Skin and Skin Structure Infections. Muijsers, R.B.R.; Jarvis, B. // Drugs;2002, Vol. 62 Issue 6, p967 

    â–´ Moxifloxacin is a fluoroquinolone antibacterial agent which attains good penetration into peripheral tissues and inflammatory fluids. The drug shows good in vitro activity against staphylococci and streptococci. Moxifloxacin is therefore a suitable option for the treatment of...

  • Similar efficacy found between tedizolid, linezolid. Cox, Amber; Schoen, John; Shafer, Emily // Infectious Disease News;Oct2013, Vol. 26 Issue 10, p21 

    The article discusses a study that compared the efficacy between tedizolid and linezolid for the treatment of patients with acute bacterial skin and structure infections, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado on September...

  • CHEMIMAGE OFFERS BIOEQUIVALANCE TECHNOLOGY FOR DRUG MAKERS.  // Biotech Business;Apr2009, Vol. 22 Issue 4, p7 

    The article reports on the plan of Pittsburgh, Pennsylvania-based ChemImage to help genetic drug makers become the first to achieve bioequivalence for nasal spray suspensions and inhalation products. According to the article, it will do so by providing a faster and more accurate way to determine...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics